Invex Therapeutics Ltd. (AU:IXC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Invex Therapeutics Ltd. has announced promising results from their collaboration with Tessara Therapeutics, showing that Exenatide significantly improves neuronal cell survival in a 3D human brain model of Alzheimer’s Disease. The study highlights Exenatide’s potential in increasing cell viability and its role as a GLP-1 receptor agonist in protecting against Alzheimer’s, a market valued at $17 billion in 2023. These findings could pave the way for further exploration of Exenatide in treating other neurodegenerative diseases.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.